A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Condition: Lymphoma, Non-Hodgkin · Leukemia, Lymphocytic, Chronic, B-Cell · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (29)
| City of Hope | Duarte, California, United States | — |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| Texas Transplant Institute | San Antonio, Texas, United States | — |
| Seattle Cancer Care Alliance | Seattle, Washington, United States | — |
| Macquarie University Hospital | Macquarie University, Australia | — |
| The Alfred Hospital | Melbourne, Australia | — |
| Linear Clinical Research Ltd | Nedlands, Australia | — |
| Scientia Clinical Research | Randwick, Australia | — |
| Chongqing University Cancer Hospital | Chongqing, China | — |
+ 17 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05424822